3-(2,6-dichloro-pyrimidin-4-yl)-oxazolidin-2-one

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 3-(2,6-dichloro-pyrimidin-4-yl)-oxazolidin-2-one
• 英文别名: 3-(2,6-dichloropyrimidin-4-yl)oxazolidin-2-one；3-(2,6-dichloropyrimidin-4-yl)-1,3-oxazolidin-2-one
• 化学式: C₇H₅Cl₂N₃O₂
• 分子量: 234.042
• InChiKey: SVQWZNJFNJLYAS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  55.3
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  2-唑烷酮 、 2,4,6-三氯嘧啶 在 sodium methansulfinate 、 四丁基溴化铵 、 potassium carbonate 作用下， 以 四氢呋喃 为溶剂， 反应 20.0h， 以73%的产率得到3-(2,6-dichloro-pyrimidin-4-yl)-oxazolidin-2-one
  参考文献：
  名称：

  2,4-二氯嘧啶和相关杂芳基氯化物的高区域选择性有机催化SN Ar胺化

  摘要：

  公开了一种使用亚磺酸钠和四丁基溴化铵作为催化剂的 2,4-二氯嘧啶与恶唑烷-2-one 和相关弱亲核胺的 SNAr 胺化的高效和区域选择性方法。该策略以区域和化学选择性方式促进各种氨基嘧啶的合成。该方法已成功用于各种活化的 N-杂芳族底物的胺化。

  DOI：

  10.1002/ejoc.201700459

文献信息

• 3-PYRIMIDIN-4-YL-OXAZOLIDIN-2-ONES AS INHIBITORS OF MUTANT IDH
  申请人：VESTAS WIND SYSTEMS A/S

  公开号：US20140235620A1

  公开（公告）日：2014-08-21

  The invention is directed to a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein R 1 -R 6 are defined herein. The invention is also directed to compositions containing a compound of formula (I) and to the use of such compounds in the inhibition of mutant IDH proteins having a neomorphic activity. The invention is further directed to the use of a compound of formula (I) in the treatment of diseases or disorders associated with such mutant IDH proteins including, but not limited to, cell-proliferation disorders, such as cancer.

  该发明涉及公式（I）的化合物或其药用盐，其中R1-R6在此处定义。该发明还涉及含有公式（I）化合物的组合物，以及利用这些化合物抑制具有新型活性的突变IDH蛋白。该发明还涉及利用公式（I）的化合物治疗与这些突变IDH蛋白相关的疾病或紊乱，包括但不限于细胞增殖紊乱，如癌症。
• [EN] 3-PYRIMIDIN-4-YL-OXAZOLIDIN-2-ONES AS INHIBITORS OF MUTANT IDH<br/>[FR] 3-PYRIMIDIN-4-YL-OXAZOLIDIN-2-ONES COMME INHIBITEURS D'IDH MUTANTE
  申请人：NOVARTIS AG

  公开号：WO2013046136A1

  公开（公告）日：2013-04-04

  The invention is directed to a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein R1-R6 are defined herein. The invention is also directed to compositions containing a compound of formula (I) and to the use of such compounds in the inhibition of mutant IDH proteins having a neomorphic activity. The invention is further directed to the use of a compound of formual (I) in the treatment of diseases or disorders associated with such mutant IDH proteins including, but not limited to, cell-proliferation disorders, such as cancer.

  该发明涉及公式(I)的化合物或其药学上可接受的盐，其中R1-R6在此处被定义。该发明还涉及含有公式(I)化合物的组合物，以及利用这些化合物抑制具有新型活性的突变IDH蛋白。该发明还涉及利用公式(I)的化合物治疗与这些突变IDH蛋白相关的疾病或紊乱，包括但不限于细胞增殖紊乱，如癌症。
• Efficient and regioselective 4-amino-de-chlorination of 2,4,6-trichloropyrimidine with N-sodium carbamates
  作者：Matteo Zanda、Patrice Talaga、Alain Wagner、Charles Mioskowski

  DOI：10.1016/s0040-4039(00)00048-4

  日期：2000.3

  4-N-Alkoxycarbonyl-2,6-dichloropyrimidines have been synthesized with good to excellent regioselectivity and yields from 2,4,6-trichloropyrimidine and N-sodium carbamates in DMF, at room temperature, in 15-30 minutes. (C) 2000 Elsevier Science Ltd. All rights reserved.
• Regioselective 4-amino-de-chlorination of trichloro- and dichloro-pyrimidines with N-sodium carbamates
  作者：Dario Montebugnoli、Pierfrancesco Bravo、Eleonora Corradi、Giovanna Dettori、Charles Mioskowski、Alessandro Volonterio、Alain Wagner、Matteo Zanda

  DOI：10.1016/s0040-4020(02)00084-4

  日期：2002.3

  4-N-Alkoxycarbonylamino-2,6-dichloro- and -2-chloro-pyrimidines have been synthesized in good to excellent regioselectivity and yields from N-sodium carbamates and, respectively, 2,4,6-trichloropyrimidine and 2,4-dichloropyrimidine, in DNIF, rt, 15-30 min. The reaction is effective also with 4,6-dichloropyrimidine, producing 4-N-alkoxycarbonylamino-6-chloropyrimidines in good yields. Some conformational features of 4-N-alkoxycarbonylamino-2,6-dichloro-pyrimidines have been investigated by X-ray diffraction and H-1 NMR spectroscopy. (C) 2002 Published by Elsevier Science Ltd.
• 3-(PYRIMIDIN-4-YL)-OXAZOLIDIN-2-ONES AS INHIBITORS OF MUTANT IDH
  申请人：Novartis AG

  公开号：EP2771337B1

  公开（公告）日：2017-08-02